EPOXOMICIN
- Product Name
- EPOXOMICIN
- CAS No.
- 134381-21-8
- Chemical Name
- EPOXOMICIN
- Synonyms
- CS-1626;BU-4061T;EPOXOMICIN;Aids010837;Aids-010837;Epoxomicin, 99.5%;BU-4061T,Aids010837;Epoxomicin(BU-4061T);EPOXOMICIN, SYNTHETIC;EPOXOMICIN;BU4061T;BU-4061T
- CBNumber
- CB3198331
- Molecular Formula
- C28H50N4O7
- Formula Weight
- 554.72
- MOL File
- 134381-21-8.mol
EPOXOMICIN Property
- Melting point:
- 107-109°
- alpha
- D24.5 -66.1 ± 0.4° (c = 0.5 in MeOH)
- Boiling point:
- 795.7±60.0 °C(Predicted)
- Density
- 1.117±0.06 g/cm3(Predicted)
- storage temp.
- -20°C
- solubility
- Soluble in DMSO (up to 10 mg/ml).
- pka
- 13.02±0.46(Predicted)
- form
- solid
- color
- White
- Stability:
- Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 2 months.
- InChIKey
- DOGIDQKFVLKMLQ-JTHVHQAWSA-N
Safety
- WGK Germany
- 3
- HS Code
- 29299090
N-Bromosuccinimide Price
- Product number
- E3652
- Product name
- Epoxomicin
- Purity
- ≥95% (HPLC), solid
- Packaging
- 50μg
- Price
- $327
- Updated
- 2024/03/01
- Product number
- 324801
- Product name
- Epoxomicin
- Purity
- InSolution, ≥95%
- Packaging
- 50μg
- Price
- $201
- Updated
- 2024/03/01
- Product number
- 324800
- Product name
- Epoxomicin, Synthetic
- Purity
- Epoxomicin, Synthetic, CAS 134381-21-8, is a potent, specific, and irreversible inhibitor of chymotrypsin-like, trypsin-like, and peptidyl-glutamyl peptide hydrolyzing activities of the proteasome.
- Packaging
- 100μG
- Price
- $360
- Updated
- 2024/03/01
- Product number
- 10007806
- Product name
- Epoxomicin
- Purity
- ≥98%
- Packaging
- 25μg
- Price
- $63
- Updated
- 2024/03/01
- Product number
- 10007806
- Product name
- Epoxomicin
- Purity
- ≥98%
- Packaging
- 50μg
- Price
- $117
- Updated
- 2024/03/01
EPOXOMICIN Chemical Properties,Usage,Production
Description
Epoxomicin (134381-21-8) is a potent, selective and cell permeable irreversible inhibitor of the 20S proteasome.1 It does not inhibit non-proteasomal proteases such as papain, chymotrypsin, trypsin, calpain and cathepsin B at concentrations up to 50 μM.1 Epoxomicin was isolated from Actinomycete strain Q996-17 and displayed in vivo antitumor activity against B16 melanoma cells.2 Epoxomicin caused a progressive model of Parkinson’s disease in various systems.3,4,5 This model has been disputed.6,7
Uses
Epoxomicin has been used:
- as an ubiquitin–proteosome system (UPS) inhibitor in pheochromocytoma PC12 cells
- as a proteasome inhibitor in mammary epithelial MCF-10A cells
- as a proteasome inhibitor in chymotryptic assay in cardiomyocytes
Uses
In studies of proteasome biology.
Definition
ChEBI: A tripeptide consisting of an Ile-Ile-Thr-NH2 sequence N-substituted on the threonamide amidic nitrogen with a (2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl group and with acetyl and meth l groups on the nitrogen of the isoleucine residue distal to the threonamide; a naturally occurring selective proteasome inhibitor with anti-inflammatory activity.
General Description
Epoxomicin is a linear peptide consisting of a threonine or serine residue with α′, β′-epoxyketone?derived from leucine or a γ,δ-dehydroleucine. It is a natural product isolated from?Actinomyces?sp., and is a cell-permeable, potent, selective and irreversible proteasome inhibitor.
Biochem/physiol Actions
Epoxomicin binds covalently to the catalytic subunits of proteasome. It forms an adduct with target proteins. It inhibits chymotrypsin-like activity of the proteasome. Epoxomicin also inhibits the nuclear factor κ light chain enhancer of activated B cells (NF-κB) mediated proinflammatory signalling pathway. It is also a potent antitumor and anti-inflammatory agent.
target
20S proteasome
storage
+4°C
References
1) Meng et al. (1999), Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo anti-inflammatory activity; Proc. Natl. Acad. Sci. USA, 96 10403 2) Hanada et al. (1992), Epoxomicin, a new antitumor agent of microbial origin; J. Antibiot. (Tokyo), 45 1746 3) McNaught et al. (2004), Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson’s disease; Ann. Neurol., 56 149 4) Matsui et al. (2010), Proteasome inhibition in medaka brain induces the features of Parkinson’s disease; J. Neurochem., 115 178 5) Metcalfe et al. (2012), Coordination between proteasome impairment and caspase activation leading to TAU pathology:neuroprotection by cAMP; Cell Death Diff., 3 e326 6) Kordower et al. (2006), Failure of proteasome inhibitor administration to provide a model of Parkinson’s disease in rats and monkeys; Ann. Neurol., 60 264 7) Bove et al. (2006), Proteasome inhibition and Parkinson’s disease modeling; Ann. Neurol., 60 260
EPOXOMICIN Preparation Products And Raw materials
Raw materials
Preparation Products
EPOXOMICIN Suppliers
- Tel
- --
- Fax
- --
- Country
- Europe
- ProdList
- 1780
- Advantage
- 38
View Lastest Price from EPOXOMICIN manufacturers
- Product
- Epoxomicin 134381-21-8
- Price
- US $15.00-10.00/KG
- Min. Order
- 1KG
- Purity
- 99%+ HPLC
- Supply Ability
- Monthly supply of 1 ton
- Release date
- 2021-07-10
- Product
- Epoxomicin 134381-21-8
- Price
- US $15.00-10.00/KG
- Min. Order
- 1KG
- Purity
- 99%+ HPLC
- Supply Ability
- Monthly supply of 1 ton
- Release date
- 2021-07-09
- Product
- EPOXOMICIN 134381-21-8
- Price
- US $1.00/KG
- Min. Order
- 1KG
- Purity
- 99%
- Supply Ability
- 1kg-1000kg
- Release date
- 2020-01-03